227 related articles for article (PubMed ID: 36243856)
1. Developing PI3K Inhibitors for Respiratory Diseases.
Fagone E; Fruciano M; Gili E; Sambataro G; Vancheri C
Curr Top Microbiol Immunol; 2022; 436():437-466. PubMed ID: 36243856
[TBL] [Abstract][Full Text] [Related]
2. The Role of Macrophages in the Development of Acute and Chronic Inflammatory Lung Diseases.
Lee JW; Chun W; Lee HJ; Min JH; Kim SM; Seo JY; Ahn KS; Oh SR
Cells; 2021 Apr; 10(4):. PubMed ID: 33919784
[TBL] [Abstract][Full Text] [Related]
3. Oligonucleotide Therapy for Obstructive and Restrictive Respiratory Diseases.
Liao W; Dong J; Peh HY; Tan LH; Lim KS; Li L; Wong WF
Molecules; 2017 Jan; 22(1):. PubMed ID: 28106744
[TBL] [Abstract][Full Text] [Related]
4. Niclosamide Ethanolamine Salt Alleviates Idiopathic Pulmonary Fibrosis by Modulating the PI3K-mTORC1 Pathway.
Pei X; Zheng F; Li Y; Lin Z; Han X; Feng Y; Tian Z; Ren D; Cao K; Li C
Cells; 2022 Jan; 11(3):. PubMed ID: 35159160
[TBL] [Abstract][Full Text] [Related]
5. Luteolin attenuates lipopolysaccharide-induced acute lung injury/acute respiratory distress syndrome by activating alveolar epithelial sodium channels via cGMP/PI3K pathway.
Hou Y; Li J; Ding Y; Cui Y; Nie H
J Ethnopharmacol; 2022 Jan; 282():114654. PubMed ID: 34537283
[TBL] [Abstract][Full Text] [Related]
6. Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway.
Saito S; Zhuang Y; Shan B; Danchuk S; Luo F; Korfei M; Guenther A; Lasky JA
PLoS One; 2017; 12(10):e0186615. PubMed ID: 29045477
[TBL] [Abstract][Full Text] [Related]
7. Targeted inhibition of PI3 kinase/mTOR specifically in fibrotic lung fibroblasts suppresses pulmonary fibrosis in experimental models.
Hettiarachchi SU; Li YH; Roy J; Zhang F; Puchulu-Campanella E; Lindeman SD; Srinivasarao M; Tsoyi K; Liang X; Ayaub EA; Nickerson-Nutter C; Rosas IO; Low PS
Sci Transl Med; 2020 Oct; 12(567):. PubMed ID: 33115948
[TBL] [Abstract][Full Text] [Related]
8. Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF.
Mercer PF; Woodcock HV; Eley JD; Platé M; Sulikowski MG; Durrenberger PF; Franklin L; Nanthakumar CB; Man Y; Genovese F; McAnulty RJ; Yang S; Maher TM; Nicholson AG; Blanchard AD; Marshall RP; Lukey PT; Chambers RC
Thorax; 2016 Aug; 71(8):701-11. PubMed ID: 27103349
[TBL] [Abstract][Full Text] [Related]
9. Autophagy Augmentation to Alleviate Immune Response Dysfunction, and Resolve Respiratory and COVID-19 Exacerbations.
Pehote G; Vij N
Cells; 2020 Aug; 9(9):. PubMed ID: 32847034
[TBL] [Abstract][Full Text] [Related]
10. PTEN: An Emerging Potential Target for Therapeutic Intervention in Respiratory Diseases.
Cai B; Yang L; Do Jung Y; Zhang Y; Liu X; Zhao P; Li J
Oxid Med Cell Longev; 2022; 2022():4512503. PubMed ID: 35814272
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic targets in lung tissue remodelling and fibrosis.
Liu G; Philp AM; Corte T; Travis MA; Schilter H; Hansbro NG; Burns CJ; Eapen MS; Sohal SS; Burgess JK; Hansbro PM
Pharmacol Ther; 2021 Sep; 225():107839. PubMed ID: 33774068
[TBL] [Abstract][Full Text] [Related]
12. The role of microRNAs in chronic respiratory disease: recent insights.
Stolzenburg LR; Harris A
Biol Chem; 2018 Feb; 399(3):219-234. PubMed ID: 29148977
[TBL] [Abstract][Full Text] [Related]
13. Is there still hope for single therapies: how do we set up experimental systems to efficiently test combination therapies?
Joos GF; Gabazza EC
Respirology; 2015 Jan; 20(1):15-23. PubMed ID: 25410652
[TBL] [Abstract][Full Text] [Related]
14. PI3K Signaling in Chronic Obstructive Pulmonary Disease: Mechanisms, Targets, and Therapy.
Pirozzi F; Ren K; Murabito A; Ghigo A
Curr Med Chem; 2019; 26(16):2791-2800. PubMed ID: 29557740
[TBL] [Abstract][Full Text] [Related]
15. Exogenous Glutamine in Respiratory Diseases: Myth or Reality?
Oliveira GP; de Abreu MG; Pelosi P; Rocco PR
Nutrients; 2016 Feb; 8(2):76. PubMed ID: 26861387
[TBL] [Abstract][Full Text] [Related]
16. CD148 Deficiency in Fibroblasts Promotes the Development of Pulmonary Fibrosis.
Tsoyi K; Liang X; De Rossi G; Ryter SW; Xiong K; Chu SG; Liu X; Ith B; Celada LJ; Romero F; Robertson MJ; Esposito AJ; Poli S; El-Chemaly S; Perrella MA; Shi Y; Whiteford J; Rosas IO
Am J Respir Crit Care Med; 2021 Aug; 204(3):312-325. PubMed ID: 33784491
[No Abstract] [Full Text] [Related]
17. Involvement of PARK2-Mediated Mitophagy in Idiopathic Pulmonary Fibrosis Pathogenesis.
Kobayashi K; Araya J; Minagawa S; Hara H; Saito N; Kadota T; Sato N; Yoshida M; Tsubouchi K; Kurita Y; Ito S; Fujita Y; Takasaka N; Utsumi H; Yanagisawa H; Hashimoto M; Wakui H; Kojima J; Shimizu K; Numata T; Kawaishi M; Kaneko Y; Asano H; Yamashita M; Odaka M; Morikawa T; Nakayama K; Kuwano K
J Immunol; 2016 Jul; 197(2):504-16. PubMed ID: 27279371
[TBL] [Abstract][Full Text] [Related]
18. Airway PI3K pathway activation is an early and reversible event in lung cancer development.
Gustafson AM; Soldi R; Anderlind C; Scholand MB; Qian J; Zhang X; Cooper K; Walker D; McWilliams A; Liu G; Szabo E; Brody J; Massion PP; Lenburg ME; Lam S; Bild AH; Spira A
Sci Transl Med; 2010 Apr; 2(26):26ra25. PubMed ID: 20375364
[TBL] [Abstract][Full Text] [Related]
19. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease.
Doukas J; Eide L; Stebbins K; Racanelli-Layton A; Dellamary L; Martin M; Dneprovskaia E; Noronha G; Soll R; Wrasidlo W; Acevedo LM; Cheresh DA
J Pharmacol Exp Ther; 2009 Mar; 328(3):758-65. PubMed ID: 19056934
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 4-Methylquinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis.
Lin S; Jin J; Liu Y; Tian H; Zhang Y; Fu R; Zhang J; Wang M; Du T; Ji M; Wu D; Zhang K; Sheng L; Li Y; Chen X; Xu H
J Med Chem; 2019 Oct; 62(19):8873-8879. PubMed ID: 31335136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
